The Tip That Traveled

The office towers of San Francisco’s financial district cast long shadows on a Tuesday afternoon in 2013 when Farhang Afsarpour picked up his phone and began making calls that would eventually attract the attention of federal regulators. The calls themselves were unremarkable—friends catching up, perhaps discussing market conditions, the kind of conversations that happen thousands of times a day in the corridors of American finance. But the timing made them something else entirely. Afsarpour had information, the kind that moves markets and changes fortunes, and he was about to share it with people who had no legal right to know.

What Afsarpour knew, and what his friends did not yet know, concerned InterMune, a Brisbane, California-based biotechnology company that had staked its future on a drug called pirfenidone. The information in his possession would soon become public, but in the hours before it did, it represented something more valuable than mere knowledge. It represented opportunity—the kind that federal securities law exists specifically to prevent.

Farhang Afsarpour wasn’t a household name, not a portfolio manager commanding billions or a hedge fund titan whose pronouncements moved indexes. He moved in different circles, close enough to the flow of corporate information to hear whispers before they became announcements, connected enough to turn those whispers into action. And on this particular day, he was about to cross a line that the Securities and Exchange Commission had spent decades drawing and redrawing, enforcing with increasing sophistication and decreasing tolerance.

The World Before the Call

To understand how Farhang Afsarpour found himself in the crosshairs of an SEC enforcement action, one must first understand the particular pressures and opportunities of biotechnology investing in the early 2010s. This was an era of enormous promise and spectacular failure, where a single FDA announcement could create or destroy billions in market capitalization in minutes. Companies like InterMune lived or died by regulatory decisions, their stock prices reflecting not current earnings but future possibilities, bets on science that might or might not pan out.

InterMune had been founded in 2000 with a mission that sounded almost noble: developing therapies for pulmonary fibrosis, a devastating disease that causes progressive scarring of lung tissue. By 2013, the company had narrowed its focus to pirfenidone, a drug that had shown promise in clinical trials. The company’s entire valuation rested on whether the FDA would approve it for use in the United States.

In the biotechnology sector, this kind of binary outcome—approval or rejection—creates a unique information asymmetry. Those inside a company know before the market does. They know before analysts issue their reports, before institutional investors adjust their positions, before retail traders see the news scroll across their screens. The delay between private knowledge and public disclosure can be measured in hours, sometimes just minutes. But in modern markets, minutes are enough.

This is where insider trading law draws its sharpest distinctions. The principle is straightforward: corporate insiders, and those who receive information from them, cannot trade on material nonpublic information. The prohibition exists to protect market integrity, to ensure that investors compete on a relatively level playing field, to prevent those with privileged access from extracting value that rightfully belongs to all market participants equally. It’s a rule that sounds simple in theory but proves endlessly complex in practice.

Farhang Afsarpour operated in a world where information flowed through professional networks, where dinner conversations could contain market-moving intelligence, where the line between permissible research and prohibited tipping could seem frustratingly vague. He was not, according to the SEC’s allegations, the original source of the inside information. That role allegedly belonged to Sasan Sabrdaran, whose connection to the nonpublic information about InterMune placed him in a position of trust—and legal jeopardy.

The Architecture of the Scheme

The mechanics of what federal prosecutors would later characterize as Securities Fraud began with a relationship. Sabrdaran allegedly had access to material nonpublic information about InterMune, information that he shared with Afsarpour. The nature of that information remains detailed in court filings: it concerned corporate developments at InterMune that had not yet been disclosed to the investing public.

Afsarpour received this information with an understanding of its significance and its provenance. He knew, according to the SEC’s complaint, that the information was not public. He knew it was material—meaning that a reasonable investor would consider it important in making investment decisions. And he knew that acting on it violated securities law. Yet he acted anyway.

But Afsarpour didn’t just trade for himself. According to the SEC’s allegations, he became what prosecutors call a “tipper,” urging friends to purchase InterMune securities based on the confidential information he possessed. This expansion of the circle—from original insider to first tippee to subsequent tippees—is a pattern familiar to securities regulators. Information, once leaked, tends to spread. Each recipient faces a choice: profit from the knowledge or respect the legal boundaries designed to protect market integrity.

The friends who received Afsarpour’s urging faced no such legal constraints only if they didn’t know the information was material and nonpublic. But Afsarpour’s communications, prosecutors would later allege, made the nature of his knowledge clear enough that recipients should have understood they were being offered an illegal advantage.

The trading that followed left a trail. Modern securities markets are comprehensively surveilled. Every trade generates records—timestamps, account numbers, broker identifications, settlement instructions. The SEC’s enforcement division has become increasingly sophisticated at pattern recognition, at identifying clusters of unusual trading activity that precede major corporate announcements. Algorithms flag anomalies. Analysts investigate. What seems like a quiet phone call between friends becomes a data point in a federal investigation.

In the case involving Afsarpour and Sabrdaran, the trading patterns around InterMune securities attracted exactly this kind of scrutiny. Positions taken shortly before public announcements. Profits realized after information became public and markets moved. The timing was too precise, the gains too consistent with foreknowledge, to be explained by luck or legitimate research.

The SEC’s complaint would eventually detail specific trades, specific dollar amounts, specific dates. These weren’t vague allegations of improper conduct. They were precise accusations backed by trading records, communication logs, and the kind of circumstantial evidence that securities prosecutors have learned to assemble into compelling cases. The numbers told a story: money made not through superior analysis or prescient risk-taking, but through information that belonged to all investors equally and had been misappropriated for private gain.

The Paper Trail

What Farhang Afsarpour might not have fully appreciated was the extent to which modern finance leaves no secrets. Every electronic communication can be subpoenaed. Every trade settles through systems that maintain permanent records. Every wire transfer creates documentation. The notion that a series of well-timed stock purchases could somehow escape notice reflects a fundamental misunderstanding of how securities regulation works in the twenty-first century.

The SEC’s investigation into the InterMune trading didn’t begin with a whistleblower’s dramatic revelation or a confession. It began, like most insider trading cases, with data. Analysts in the enforcement division’s Market Abuse Unit noticed unusual trading patterns in InterMune securities ahead of significant corporate announcements. The volume was suspicious. The timing was suspicious. The profit margins suggested foreknowledge.

From there, the investigation followed standard procedures: subpoena the trading records, identify the accounts involved, trace the relationships between the traders and potential sources of inside information. Modern securities enforcement operates with an investigative toolkit that would have seemed impossible a generation ago. Phone records, email servers, text message archives—all can be obtained through legal process. The web of communication that seemed private at the time becomes, in retrospect, a map of illegal activity.

The SEC’s complaint against Afsarpour and Sabrdaran would eventually paint a detailed picture of who knew what and when. Sabrdaran, according to prosecutors, was the source—the person with access to material nonpublic information about InterMune. His breach of duty in sharing that information constituted the predicate offense, the original sin from which all subsequent violations flowed. Afsarpour, in receiving that information and trading on it, became liable as a tippee. And by urging his friends to trade, he assumed the additional role of a downstream tipper, further propagating the misuse of confidential corporate information.

The legal theory underlying the SEC’s case was well-established. Under securities law, a tippee inherits the insider’s duty not to trade on material nonpublic information. The tippee becomes liable when they know or should know that the insider breached a fiduciary duty by disclosing the information, and the insider received a personal benefit from the disclosure. That benefit need not be monetary; courts have recognized that maintaining friendships, building goodwill, and enhancing one’s reputation can all constitute sufficient personal benefit to establish liability.

In Afsarpour’s case, the complaint alleged facts sufficient to establish all these elements. Sabrdaran allegedly provided the information to Afsarpour in the context of a relationship that provided Sabrdaran with personal benefit. Afsarpour knew or should have known that the information was confidential. He traded on it. And he encouraged others to trade on it.

The Unraveling

By the time federal investigators approached Farhang Afsarpour, the case against him had already been substantially built. This is how white-collar prosecutions typically work. The targets learn they’re under investigation late in the process, after evidence has been gathered, witnesses interviewed, and legal theories refined. The first indication that something is wrong often comes in the form of a subpoena or, in civil enforcement actions, a Wells notice—the SEC’s courtesy warning that charges are likely forthcoming.

The SEC’s investigation culminated in formal charges against both Afsarpour and Sabrdaran. The complaint alleged violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder—the broad anti-fraud provisions that form the foundation of insider trading enforcement. These are the statutes that prohibit deceptive practices in connection with the purchase or sale of securities, the legal framework that transforms information asymmetry into actionable fraud.

For Sabrdaran, the allegations were particularly serious. As the alleged source of the inside information, he faced not only disgorgement of profits and civil penalties but also what prosecutors call collateral consequences. The SEC sought, and would eventually obtain, an officer and director bar against him—a prohibition on serving in corporate leadership roles at any public company. For someone in finance, this kind of ban can effectively end a career, transforming a regulatory violation into a professional death sentence.

Afsarpour faced his own reckoning. The trades he had made, and the trading he had encouraged, exposed him to liability that would eventually be quantified in the final judgment. The SEC’s enforcement action sought disgorgement—the return of ill-gotten gains—plus prejudgment interest to account for the time value of money improperly obtained.

Defending against insider trading charges presents unique challenges. The government doesn’t need to prove that defendants explicitly discussed the illegal nature of their conduct. It doesn’t need recorded conversations where someone says “this is inside information and we shouldn’t trade on it.” The case can be built on timing, on patterns of communication, on the obvious inference that someone with no apparent reason to trade suddenly does so just before a major announcement. Circumstantial evidence, properly marshaled, can be devastating.

Neither Afsarpour nor Sabrdaran took their cases to trial. This, too, is typical in SEC enforcement actions. The agency has substantial advantages in civil litigation: a lower burden of proof than criminal prosecution, extensive investigative powers, and decades of precedent supporting its legal theories. The calculus often favors settlement, accepting liability and negotiating over the financial consequences rather than risking a judgment that could be even more severe.

The Price of Knowledge

On June 30, 2017, the SEC announced the final judgment against Farhang Afsarpour and Sasan Sabrdaran. The numbers told part of the story. The judgment ordered disgorgement and prejudgment interest totaling $386,671—the quantified value of trading profits that never should have been earned, extracted from markets through information that should never have been privately held.

The dollar figure itself might seem modest compared to the blockbuster insider trading cases that generate headlines. There were no multimillion-dollar mansions seized, no fleets of luxury cars forfeited, no offshore accounts drained. But the amount was hardly the point. The enforcement action served multiple purposes beyond mere recovery of profits.

First, it vindicated the principle that material nonpublic information belongs to all market participants equally. Every investor who traded InterMune securities during the period when Afsarpour and his circle were acting on inside information was potentially disadvantaged, buying when they should have sold or selling when they should have held. The disgorgement judgment couldn’t make those unknown victims whole, but it could strip away the advantage the insiders had obtained.

Second, the judgment carried reputational consequences that far exceeded the financial penalties. Afsarpour’s name would now appear permanently in SEC enforcement databases, in legal search engines, in the background checks that investment firms and financial institutions routinely conduct. The securities industry has a long memory for regulatory violations. A final judgment in an insider trading case becomes a scarlet letter, limiting professional options and marking its bearer as someone who crossed lines that most market participants successfully avoid.

For Sabrdaran, the officer and director bar imposed additional constraints. The ban meant permanent exclusion from certain corporate roles, a recognition by regulators that his conduct demonstrated unfitness for positions of trust in public companies. This wasn’t a temporary penalty or a fine that could be paid and forgotten. It was a structural prohibition that would follow him indefinitely.

The SEC’s announcement of the final judgment served another purpose: general deterrence. Every enforcement action sends a message to the broader market about what conduct will and won’t be tolerated. The agency can’t catch every instance of insider trading—the practice undoubtedly continues despite decades of enforcement efforts. But each publicized case raises the perceived risk of getting caught, shifts the cost-benefit calculation that potential violators make, and reinforces social norms against the misuse of confidential information.

The Broader Context

The Afsarpour-Sabrdaran case unfolded against a backdrop of intensifying scrutiny of insider trading throughout the 2010s. Federal prosecutors in Manhattan had made securities fraud a priority, bringing high-profile cases against hedge fund managers, corporate executives, and the networks of consultants and analysts who facilitated information leakage. The SEC, working parallel to criminal prosecutors, ramped up its own enforcement efforts, deploying increasingly sophisticated data analytics to identify suspicious trading patterns.

This enforcement environment reflected a growing recognition that insider trading corrodes market integrity in ways that extend beyond the immediate profits earned by violators. When investors lose confidence that markets are fair, they withdraw from participation or demand higher returns to compensate for the risk of being on the wrong side of information asymmetries. This increases the cost of capital for legitimate businesses and reduces overall economic efficiency. The harm, though diffuse and difficult to quantify for any individual victim, is real and substantial in aggregate.

The biotechnology sector presented particular challenges for enforcement. The binary nature of many biotech catalysts—FDA approvals or rejections, clinical trial results, patent decisions—created enormous incentives for insider trading. A single piece of information could move a company’s stock price by 50 percent or more in a matter of hours. The potential profits from foreknowledge were correspondingly large. And the complexity of the industry created cover for those seeking to obscure the source of their trading decisions. Someone who claims to have made a bet based on scientific analysis or industry expertise is harder to disprove than someone trading on more transparent corporate events.

Yet the InterMune case demonstrated that complexity alone wouldn’t protect illegal traders. The SEC had developed expertise in biotech enforcement, learning to distinguish between legitimate expert network consultations and illegal tipping arrangements, between permissible mosaic theory investing and prohibited use of material nonpublic information. The agency’s complaint against Afsarpour and Sabrdaran reflected this sophistication, laying out not just suspicious trading but the relationships and communications that explained how nonpublic information had migrated from corporate insider to ultimate trader.

What Remains Unresolved

The final judgment against Farhang Afsarpour closed one chapter but left others open. The SEC’s announcement mentioned Sabrdaran and Afsarpour specifically, but the complaint had referenced others who traded on the tips—the friends Afsarpour had urged to purchase InterMune securities. Were they investigated? Did they face enforcement actions of their own? The public record is silent on these questions.

This is one of the peculiarities of securities enforcement: the cases that become public often represent only a fraction of the underlying conduct. Some participants cooperate with investigators, providing information in exchange for lenient treatment. Others escape prosecution because the evidence against them is insufficient or because enforcement resources are limited and must be prioritized. The visible enforcement action is the tip of an investigative iceberg whose full dimensions remain hidden.

For InterMune itself, the story had its own resolution. In 2014, the company was acquired by Roche for approximately $8.3 billion, a validation of the science behind pirfenidone and a windfall for shareholders who had held through the regulatory uncertainty. The drug ultimately received FDA approval for the treatment of idiopathic pulmonary fibrosis. The legitimate investors who had taken risk and waited for outcomes earned their returns. The illegal traders who had short-circuited that process with inside information gained nothing but regulatory sanction and professional disgrace.

The broader questions raised by the case remain evergreen. How much enforcement is enough to deter insider trading without chilling legitimate market activity? How can regulators distinguish between the sophisticated pattern recognition that represents valuable analysis and the suspicious trading that suggests illegal foreknowledge? How do we balance the privacy interests of market participants against the surveillance necessary to detect violations? These questions have no permanent answers, only ongoing negotiations between regulators, market participants, and the courts that adjudicate disputes between them.

The Scene After

Somewhere in the records of the Securities and Exchange Commission, in the databases that track enforcement actions and the files that document market manipulation, the case of Farhang Afsarpour occupies a few megabytes of storage. The documents detail the trades, the timelines, the profits earned and subsequently disgorged. They quantify, as precisely as law and accounting allow, the value of information misused and the penalties imposed for that misuse.

But the case also exists in less tangible forms: as a deterrent example in the compliance training that financial professionals must complete, as a case study in the business ethics courses taught at universities, as a data point in the academic literature that analyzes insider trading enforcement. It has become part of the institutional memory of securities regulation, one more precedent that shapes how future cases are investigated, charged, and resolved.

For Afsarpour himself, the resolution represented both an ending and a beginning. The SEC case was concluded, the financial penalties determined, the public record established. What came after—how he rebuilt his professional life, what lessons he took from the experience, whether he remained in finance or left it behind—remains his private story, one that the public record doesn’t capture and regulatory filings don’t reveal.

The morning after the SEC announced the final judgment, trading in biotechnology stocks continued as it always does. Analysts issued reports. Portfolio managers adjusted positions. Retail investors checked their accounts. The markets absorbed the news of another enforcement action and moved on, as markets do, always forward, always seeking the next opportunity, the next risk, the next information edge that might translate into profit.

And somewhere, in offices and trading floors and home computers across the country, people with access to material nonpublic information made their daily choice: to respect the boundaries that separate legitimate investing from illegal trading, or to cross those boundaries and risk becoming the subject of the next enforcement action, the next case study, the next cautionary tale about the price of trading on secrets that were never theirs to use.